Ethnic Variations in Inflammatory Bowel Diseases Among Israel’s Populations

Mahmud Mahamid MD2,4,5,*, Ariella Bar-Gil Shitrit MD4,*, Hana Amara MD3, Benjamin Koslowsky MD1, Rami Ghantous RN4,6 and Rifaat Safadi MD7

1Department of Gastroenterology, Shaare Zedek Medical Center, Jerusalem, Israel
2Department of Internal Medicine and 3Gastroenterology Institute, Nazareth Hospital EMMS, Nazareth, Israel
4Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel
5Department of Internal Medicine and 6Liver Unit, Holy Family Hospital, Nazareth, Israel
7Department of Gastroenterology and Liver Diseases, Hadassah–Hebrew University Medical Center, Ein Kerem Campus, Jerusalem, Israel

ABSTRACT: Background: Crohn’s disease and ulcerative colitis are the two major classic presentations of inflammatory bowel diseases (IBD). Studies have shown a wide variation in the incidence and prevalence attributed to different geographic and ethnic populations.

Objectives: To assess the clinical characteristics of IBD among Arabs in Israel and to compare them to characteristics of IBD among Ashkenazi Jews.

Methods: This retrospective, comparative study compared the clinical characteristics of IBD among 150 Arabs from the Holy Family Hospital and the Nazareth Hospital EMMS, both located in Nazareth, Israel, to those of 97 age- and sex-matched Ashkenazi Jewish patients from Shaare Zedek Medical Center, Jerusalem, Israel.

Results: The Arab cohort, which included 106 patients (70%) with Crohn’s disease and 44 (29%) with ulcerative colitis, was compared to 97 Ashkenazi patients (81% with Crohn’s disease and 17% with ulcerative colitis) (P < 0.05). Alcohol consumption was found in both groups, but Arabs smoked more (46% vs. 12%, respectively, P < 0.05). Obstructive phenotype was lower in Arabs (10% vs. 32%, P < 0.05). 5-aminosalicylic acid and anti-tumor necrosis factor alpha were prescribed for the Arab and Ashkenazi groups (89% and 21%, respectively). The need for surgical intervention due to disease severity and/or complications was not significant (22% vs. 24%).

Conclusions: Despite similar reports of NOD2/CARD15 mutations, Crohn’s disease is more common than ulcerative colitis within the Arab-Israeli population. Increased smoking rates may explain milder disease severities in Arabs, as reflected by lower obstructive pattern and frequent use of milder therapeutic modalities.

KEY WORDS: Crohn’s disease, ethnic differences, inflammatory bowel diseases (IBD), ulcerative colitis

Crohn’s disease and ulcerative colitis are the two major classic presentations of inflammatory bowel diseases (IBD). Many studies have shown a wide variation in the incidence and prevalence attributed to different geographic and ethnic populations [1,2]. This finding is also true among the rate of IBD in various ethnic groups in Asia. It appears that certain racial groups are more susceptible to IBD. While there is a genetic predisposition, environmental factors may be responsible for these differences. Moreover, the clinical phenotypes, response to therapies, and rates of complications may differ among distinct ethnic groups [3-7].

Arab countries have been marked as an area with low incidence of IBD, although biases may arise from low diagnostic awareness, and a high incidence of infectious diarrhea [3]. Nonetheless, it is clear that the incidence and prevalence rates of IBD among Arabs in Israel are low compared with that of the Ashkenazi Jewish population [4,5]. Approximately 20% of the population in Israel is Arab [4,5]. Available studies suggest an increased incidence of IBD among Arabs living in Israel compared with Arabs in other countries. Published data suggest that the disease course of ulcerative colitis is milder in Arabs from Middle Eastern Arab countries compared to that reported in Western countries, whereas Crohn’s disease has a similar clinical course to that described in Western countries [8-11].

The Jewish population in Israel is heterogeneous and is historically divided into two major groups: Ashkenazi Jews from Central and Eastern Europe and non-Ashkenazi Jews from the Mediterranean, North Africa, and Asia. The incidence and prevalence of inflammatory bowel diseases has been reported to be twofold to fourfold higher in Ashkenazi Jews than in non-Jewish Caucasians [12].

Previously published data showed that the carrier rate of the NOD2 polymorphisms (R702W, G908R, and 1007fsInsC) is higher in Ashkenazi Jewish Crohn’s disease patients than in non-Ashkenazi Jews [13]. In addition, Ashkenazi Jews display a 1.9-fold higher frequency of variant MTHFR 677T than do non-Ashkenazi Jews [14,15].
The aims of this study were to assess the clinical characteristics of IBD among Arabs in Israel, and to compare the disease characterization to that of Ashkenazi Jews with IBD.

PATIENTS AND METHODS
This retrospective, comparative study compared the clinical characteristics of IBD among 150 Arabs from the Holy Family Hospital and the Nazareth Hospital EMMS, both located in Nazareth, Israel, to those of 97 age- and sex-matched Ashkenazi Jewish patients from Shaare Zedek Medical Center in Jerusalem, Israel. Informed consent was waived due to the non-interventional study design.

Following the approval of the local ethics review board at EMMS Nazareth Hospital, this study included all IBD patients seen at that medical center from January 2005 to December 2014. The data collected from medical records included age, gender, anthropometric parameters, disease type, disease extension, endoscopic and radiological findings, pathology and laboratory test results, disease management, complications, need for surgical intervention, hospitalizations, and risk factors for IBD.

The diagnosis of IBD and the ulcerative colitis or Crohn’s disease subtype were confirmed through clinical, endoscopic, pathological, and radiological investigations. Crohn’s disease was defined as the presence of discontinuous lesions, aphthous ulcers, and cobblestone pattern on endoscopy. Histological evidence of Crohn’s disease included focal ulcerations with acute and chronic inflammation. Radiological evidence included strictures, perforations, and fistulas. Endoscopic findings of ulcerative colitis included continuous superficial lesions, proximal extension from rectum, loss of vascular pattern, and areas of spontaneous bleeding. Histological evidence of ulcerative colitis included crypt abscesses and gland atrophy. Disease extension was defined using the terms proctitis, left side colitis, and pancolitis for ulcerative colitis. Crohn’s disease extension, however, was described by small bowel involvement only, ileocolitis, and colitis.

Complications of IBD and the presence of extra-intestinal manifestations were recorded. Disease management was categorized as medical, surgical, or both. Medication history was obtained through a careful review of clinical records. Anthropometric measurements included height, weight, and body mass index.

Patients were considered active smokers when current cigarette use was confirmed at the most recent documentation of smoking history. Patients were considered prior smokers if they reported previous cigarette use but denied current smoking at the most recent documentation of smoking history. Nonsmokers were those who denied any history of cigarette use. A similar classification was used for alcohol consumption.

STATISTICAL ANALYSIS
Statistical analyses were performed using IBM Statistical Package for the Social Sciences statistics software, version 19 (SPSS, IBM Corp, Armonk, NY, USA). Continuous variables were expressed as mean ± standard deviation. Chi-square was used to test differences in categorical variables between the two groups, and analysis of variance (ANOVA) or t-test was used for comparisons of continuous variables. A multiple logistic regression analysis was used to determine the association between the examined factors and cardiovascular risk. A P value of < 0.05 was considered significant.

RESULTS
The study included 248 ethnically diverse subjects: 150 Arab IBD patients and 97 (39%) Ashkenazi Jewish IBD patients. The Arab cohort included 28% (42/150) Muslims and the rest identified as Christian Arabs. Other baseline characteristics of the two groups are presented in Table 1. The percentage of males in the Arab group was higher. Among the Arab patients, 106 (70%) were diagnosed with Crohn’s disease and 44 (29%) with ulcerative colitis, compared to 81% and 17%, respectively in the Ashkenazi Jewish cohort (P < 0.05). Mean age at diagnosis was 19 ± 12 years among the Arab group and 20 ± 10 years for the Ashkenazi Jewish group. Mean age at the end of follow-up was 23 ± 11 vs. 32 ± 10 years, respectively (P < 0.05). This difference was due to shorter follow-up periods for the Arab patients of 3 ± 7.1 vs. 6 ± 11 years, respectively (P < 0.05). Family history of the disease was found significantly less often in Arab IBD cases (7% vs. 16%, respectively, P < 0.05). Smoking was significantly more common among Arab IBD patients (70/150, 46%) compared with 7% (7/97) of Ashkenazi Jews (P < 0.05). Reported alcohol consumption was lower (5%, 8/150) among Arab patients compared to 9% (9/97) among the Ashkenazi Jewish cohort (P < 0.05).

The disease manifestations and natural history showed different outcomes in both groups [Table 2]. Obstructive phenotype

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Arab group N=150</th>
<th>Ashkenazi Jewish group N=97</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male gender (%)</td>
<td>80 (53%)</td>
<td>56 (58%)</td>
<td>NS</td>
</tr>
<tr>
<td>Age at end of follow-up, median ± SD, years</td>
<td>23 ± 11</td>
<td>32 ± 10</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Age at diagnosis, median ± SD, years</td>
<td>19 ± 12</td>
<td>20 ± 10</td>
<td>NS</td>
</tr>
<tr>
<td>Disease duration, mean ± SD, years</td>
<td>3 ± 7.1</td>
<td>6 ± 11</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Crohn’s disease (%)</td>
<td>106 (70%)</td>
<td>79 (81%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Family history of inflammatory bowel disease (%)</td>
<td>11 (7%)</td>
<td>15 (16%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Current smoker (%)</td>
<td>70 (46%)</td>
<td>7 (7%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Alcohol consumption</td>
<td>8 (5%)</td>
<td>9 (9%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>NS = not significant, SD = standard deviation</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Patient characteristics of both study groups
was noted in 10% of the Arab cohort (15/150), compared with 32% (31/97) of the Ashkenazi Jewish cohort (P < 0.05). Disease extension also differed. Most Arab Crohn’s disease patients (38%, 58/150) had ileocolitis or colitis, while 50% (48/97) of the Ashkenazi Jewish had small bowel disease and ileocolitis. Proctitis and/or left side colitis was present in 84% of Arab ulcerative colitis patients compared with 55% in Ashkenazi Jews, who had pancolitis. Extra-intestinal manifestations recorded within 19% (28/150) of the Arab group and 8% (8/97) of the Ashkenazi Jewish cohort. Interestingly, group skin manifestation and axial arthropathy were high (84%) in the Arab group with regard to extra-intestinal manifestation in the Arab group than Ashkenazi Jewish group. The rate of hospitalization due to disease exacerbation was less frequent among Arabs, but without clinical significance (54% vs. 70%, respectively). The need for surgical intervention due to disease severity and/or complications was not significant between the two groups (22% vs. 24%).

Medical therapy showed significantly higher use of 5-aminosalicylic acid (5-ASA) among the Arab group (89%) (134/150) compared with only 21% (20/97) of the Ashkenazi Jewish group (P < 0.05). Immunomodulators were used more often among Arabs (23%), compared to 16% among Ashkenazi Jews (P < 0.05). The use and need for steroids was similar between the Arab group and Ashkenazi Jewish (41% vs. 42%, respectively). However, the use of biological drugs was significantly lower among the Arab group than the Ashkenazi Jewish group (4% vs. 42%, respectively; P < 0.05). The main results are presented in Figure 1.

**DISCUSSION**

Despite similar reported reports of NOD2/CARD15 mutations, our study showed that Crohn’s disease and ulcerative colitis are more common within the Arab-Israeli population than the Ashkenazi Jewish-Israeli population. The fact that ulcerative colitis is less common among Arabs may be due to detection bias, as symptoms of ulcerative colitis can be milder and fewer patients may seek medical advice; however, among Crohn’s dise-

### Table 2. Disease characteristics of both study groups

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Arab group N=150</th>
<th>Ashkenazi Jewish group N=97</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstructive phenotype (%)</td>
<td>15 (10%)</td>
<td>31 (32%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Ileocolitis or Crohn’s colitis (%)</td>
<td>58 (38%)</td>
<td>48 (50%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Extra-intestinal manifestation (%)</td>
<td>28 (19%)</td>
<td>8 (8%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Surgical intervention (%)</td>
<td>33 (22%)</td>
<td>23 (24%)</td>
<td>NS</td>
</tr>
<tr>
<td>5-aminosalicylic acid (%)</td>
<td>134 (89%)</td>
<td>20 (21%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Immunomodulatory drug (%)</td>
<td>34 (23%)</td>
<td>15 (16%)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td>Biological treatment (%)</td>
<td>6 (4%)</td>
<td>41 (42%)</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>

NS= not significant

## Figure 1. The main differences among the both study groups

![Figure 1](image-url)
The location and extension of the IBD was distinct in the groups. While proctitis (involvement of rectum) and left side colitis were predominately among Arabs with ulcerative colitis, pancolitis was also less predominate among Ashkenazi Jewish patients. Similarly, Crohn’s disease was located more proximally in Ashkenazi Jews with isolated small bowel involvement and/or ileocecal involvement, compared with colonic and/or ileocolonic involvement among Arabs.

The prevalence of extra-intestinal manifestations was not similar between the two groups, but skin manifestations and axial arthropathy were more common among Arabs compared to peripheral arthropathy among Ashkenazi Jews.

The natural history of the disease appears to be distinct in both ethnic groups. The obstructive pattern is the predominant characteristic of Crohn’s disease among Ashkenazi Jewish patients. Our study is limited by its retrospective character. Other limitations were the small population size. There might have been a selection bias, as subjects were recruited from patients who visited the hospital for health examinations; thus, they were more concerned about their health status. Moreover, the comparison between the treatment modalities in both ethnic groups is problematic as data were collected from different therapy centers with varying therapy protocols.

CONCLUSIONS

We found different characteristics and natural history of IBD between the Arab and Ashkenazi Jewish populations in Israel. Crohn’s disease is more prevalent than ulcerative colitis in Arabs. Disease manifestations appear to be less severe, with more use for and need of 5-ASA, and a low rate of biological drug use. Smoking might be suggested as a protective factor among this ethnic group, although most were Crohn’s disease patients.

Acknowledgements

The authors thank Dr. Shahir Abu-Khalil for help in data acquisition.

Correspondence

Dr. M. Mahamid
Dept. of Internal Medicine, Nazareth Hospital EMMS, Nazareth 16100, Israel
Phone: (972-4) 602-8851
Fax: (972-4) 755-9551
email: mahmudmahamid@yahoo.com

References


“There is a fountain of youth: it is your mind, your talents, the creativity you bring to your life and the lives of the people you love. When you learn to tap this source, you will have truly defeated age”

Sophia Loren (born 1934), actor and singer